Hologic/$HOLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Ticker
$HOLX
Sector
Primary listing
Employees
7,063
Headquarters
Website
Hologic Metrics
BasicAdvanced
$14B
26.70
$2.41
0.49
-
Price and volume
Market cap
$14B
Beta
0.49
52-week high
$82.66
52-week low
$51.90
Average daily volume
1.5M
Financial strength
Current ratio
3.555
Quick ratio
2.585
Long term debt to equity
51.812
Total debt to equity
51.812
Interest coverage (TTM)
7.86%
Profitability
EBITDA (TTM)
1,241.7
Gross margin (TTM)
60.86%
Net profit margin (TTM)
13.79%
Operating margin (TTM)
23.43%
Effective tax rate (TTM)
17.54%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
6.69%
Return on equity (TTM)
11.38%
Valuation
Price to earnings (TTM)
26.696
Price to revenue (TTM)
3.647
Price to book
2.96
Price to tangible book (TTM)
25.74
Price to free cash flow (TTM)
16.068
Free cash flow yield (TTM)
6.22%
Free cash flow per share (TTM)
4.011
Growth
Revenue change (TTM)
1.29%
Earnings per share change (TTM)
-17.18%
3-year revenue growth (CAGR)
-8.23%
10-year revenue growth (CAGR)
4.34%
3-year earnings per share growth (CAGR)
-25.85%
10-year earnings per share growth (CAGR)
17.89%
What the Analysts think about Hologic
Analyst ratings (Buy, Hold, Sell) for Hologic stock.
Bulls say / Bears say
Private equity buyers TPG and Blackstone have proposed a leveraged buyout valuing Hologic at $70–$72 per share, a 30% premium to current trading levels, signaling potential upside (Financial Times).
In Q2, Hologic’s molecular diagnostics division posted revenue growth, benefiting from strong demand for sexual health and COVID-19 tests, highlighting resilience in its high-margin diagnostics segment (Financial Times).
Hologic shares traded near record highs above $83 as recently as August 2024, showing substantial recovery potential from present levels (Financial Times).
Hologic’s breast health segment saw revenues decline in Q2, with reduced equipment sales impacting the division as core mammography capital sales dropped (Financial Times).
Hologic lowered its fiscal 2025 profit outlook, citing uncertainty about U.S. tariffs on China and Costa Rica manufacturing, which is putting pressure on margins (Reuters).
The company warned that demand for gantry placements will be lower in 2025, signaling ongoing headwinds for its breast imaging equipment business (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Hologic Financial Performance
Revenues and expenses
Hologic Earnings Performance
Company profitability
Hologic News
AllArticlesVideos
Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference
Business Wire2 weeks ago
Hologic raises annual profit forecast on diagnostic and surgical demand
Reuters2 months ago
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hologic stock?
Hologic (HOLX) has a market cap of $14B as of September 14, 2025.
What is the P/E ratio for Hologic stock?
The price to earnings (P/E) ratio for Hologic (HOLX) stock is 26.7 as of September 14, 2025.
Does Hologic stock pay dividends?
No, Hologic (HOLX) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Hologic dividend payment date?
Hologic (HOLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Hologic?
Hologic (HOLX) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.